The Key to This $500B Market Is in Your Bloodstream
Every year, $240B is spent on treating the symptoms of osteoarthritis, a disease that leads to joint degradation and, eventually, immobility. With 500M people afflicted, its total addressable market is worth over $500B.
But not a single therapy has been able to actually stop it. The answer, it turns out, has been inside us all along.
A startup named Cytonics discovered the human body already produces a protein designed to protect cartilage. It just doesn’t produce enough where it's needed most. So Cytonics harnessed it.
Their first-generation therapy has already treated 10,000+ patients. Now they've engineered a 200% more potent, mass-producible version pushing toward FDA approval.
But that's only scratching the surface of why 7,000+ investors have already backed Cytonics.
- Breakthrough: If approved, Cytonics treatment could be the first true disease-modifying treatment for osteoarthritis in history.
- Traction: With a Phase 1 human safety trial completed with zero adverse events, Cytonics has the clinical proof to back their science.
- Opportunity: Everyday investors have the limited-time chance to participate in an early-stage biotech investment opportunity that’s historically been reserved for VCs and institutional investors.
Now’s your chance to claim a piece at the pre-clinical stage as an early-stage investor. Don’t miss out.
Invest by March 26 to maximize your early-stage stake with time-sensitive bonus stock offers.
This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/